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Abstract
in 2015, the world Health Organization (wHO) recommended that all people living with Hiv (PLwH) should start 
antiretroviral therapy (ART) irrespective of clinical or immune status. This recommendation followed almost 20 years of 
research into the clinical and population-level benefits and risks of starting ART early compared with deferring treatment. 
This article summarises the ways in which observational data support the work of wHO, including the support provided 
by the international epidemiology Databases to evaluate AiDS (ieDeA), taking the example of ‘treat all’.
Introduction
in 2015, the world Health Organization (wHO) recommended 
that all people living with Hiv (PLwH) should start antiretroviral 
therapy (ART) irrespective of clinical or immune status [1]. This 
recommendation followed almost 20 years of research into the 
clinical and population-level benefits and risks of starting ART 
early compared with deferring treatment [2].
The wHO ‘treat all’ recommendation was supported by evidence 
from randomised trials showing significant clinical benefits and 
a reduced risk of Hiv transmission following immediate ART ini-
tiation [3-5]. The randomised trials confirmed an association that 
was reported by prior observational studies [6-9]; however, 
observational data alone were insufficient for the wHO guidelines 
panel to make a ‘treat all’ recommendation when this question 
was first assessed in 2013. Nevertheless, the observational evi-
dence helped to strengthen the rationale for this recommendation. 
Observational studies have also provided important additional 
evidence supporting the feasibility of implementing the ‘treat 
all’ approach, and these studies continue to generate insights 
into the challenges and benefits of a treat-all policy across dif-
ferent settings and populations.
This article summarises the ways in which observational data 
support the work of wHO, including the support provided by 
the international epidemiology Databases to evaluate AiDS (ieDeA) 
[10], taking the example of ‘treat all’ (see Table 1).
Role of observational data in WHO guidelines
The development of high-quality guidelines relies on a systematic 
review of the evidence and an appraisal of the certainty of the 
evidence. Guideline development processes have widely adopted 
the Grading of Recommendations Assessment, Development, and 
evaluation (GRADe) framework [16], which, following a long-
standing approach to ranking evidence [17], rates randomised 
trials as generally providing high-quality evidence for questions 
of intervention effect, and observational studies as providing 
low-quality evidence (in certain exceptional situations obser-
vational studies can be considered to provide evidence of high 
quality [18]).
wHO adopted the GRADe approach in 2008, following public 
criticism that many wHO guidelines at the time relied too heavily 
or exclusively on expert opinion [19]. in contrast to clinical practice 
guidelines, wHO guidelines aim to make recommendations from 
a public health perspective, and are thus primarily intended for 
ministries of health and programme managers in low- and middle-
income settings, rather than individual clinicians. As such, the 
formulation of wHO recommendations relies not only on informa-
tion about comparative effectiveness and harms, but also con-
siderations about the feasibility, acceptability and resource 
requirements for implementing a given intervention or set of 
interventions as well as complex interventions. while randomised 
trials remain the gold standard study design for assessing efficacy 
and safety of clinical interventions, observational studies are often 
a better way – and in some cases the only way – to assess inter-
vention effectiveness in routine settings.
wHO also has a responsibility to evaluate the uptake and impact 
of the recommendations it makes, and these evaluations rely on 
observational research from implementation in routine programmes. 
Lessons from these studies serve to highlight challenges in imple-
mentation, which in turn can inform priorities for future guidance 
(Figure 1).
From treating the sickest to ‘treat all’: 
formulating recommendations
wHO first considered making a recommendation to start ART in 
all people living with Hiv irrespective of clinical or immune status 
in 2013. At the time, there were no available data from randomised 
trials with respect to clinical benefit, and guideline deliberations 
were primarily informed by observational data and mathematical 
modelling. The 2013 wHO Guideline Development Group con-
cluded that there was insufficient evidence to recommend ‘treat 
all’, and wHO instead recommended that the CD4 cell count 
threshold for stating ART be raised from ≤350 cells/mm3 to ≤500 
cells/mm3 [20].
Randomised controlled trial evidence was available demonstrating 
the benefit of providing immediate treatment in the context of 
serodiscordant partnerships to reduce Hiv transmission [5], and 
this recommendation was included in the wHO 2013 guidelines.
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Table 1. Analysis of data from the international epidemiology Databases to evaluate AiDS (ieDeA) to inform wHO guidelines
Guideline Evidence contributed Analyses performed
wHO 2010 ART guidelines for Hiv infection 
in infants and children
Definition of immunological failure in 
children on ART
Risk of mortality associated with different ages and CD4 
values in children on ART [11]
wHO 2013 Consolidated guidelines on the 
use of antiretroviral drugs for treating and 
preventing Hiv infection
Support for ART for all children aged
<5 years irrespective of disease severity
Causal modelling of observational data comparing 
mortality with immediate versus deferred ART in children 
aged 1–5 years [12]
wHO 2016 consolidated guidelines on the 
use of antiretroviral drugs for treating and 
preventing Hiv infection
Support for ART for all children aged
<15 years irrespective of disease severity
Causal modelling of observational data comparing 
mortality and growth with immediate versus deferred 
ART in children aged 1–15 [13]
wHO 2017 guidelines for managing advanced 
Hiv disease and rapid initiation of 
antiretroviral therapy
Definition of burden of advanced Hiv 
disease in adults and children
Proportion of adults in ieDeA and COHeRe 
collaborations presenting with advanced Hiv disease; 
proportion of children aged<5 years in ieDeA-SA 
presenting with advanced Hiv disease [14,15]
Figure 1. The contribution of observational data to guideline development at wHO
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years later, once data from the START and TeMPRANO randomised 
trials became available [3,4]. However, these trials did not include 
children, and the ‘treat all’ recommendation across all age groups, 
including children, was supported by observational data (17 cohort 
studies) and mathematical modelling [26,27] (Table 1).
The wHO recommendation to treat all people living with Hiv 
also raised questions regarding how quickly ART should be initi-
ated following confirmation of Hiv diagnosis. Removing the need 
to have the results of clinical or laboratory assessments on hand 
prior to starting ART opens up the possibility to start ART on 
the same day that an Hiv diagnosis is confirmed. in 2017, wHO 
recommended that ART should be offered within 7 days following 
a confirmed Hiv diagnosis, including the offer of initiating ART 
on the same day as diagnosis [28]; this recommendation was 
informed by data from four randomised trials and 11 observational 
studies [29].
Benefits and challenges of ‘treat all’:  
assessing implementation
The clinical benefits of ‘treat all’ are no longer disputed, and this 
recommendation has been adopted by almost all countries world-
wide [30]. Questions remain, however, regarding the feasibility 
of implementation and the extent to which the benefits seen in 
clinical trials will be realised in routine programme settings [31].
Drawing on both ieDeA data and information retrospectively 
gathered on the nature and timing of country-specific ART guide-
line expansion, a recently published analysis from the ieDeA–wHO 
Collaboration [32] found that ART guideline expansion supporting 
earlier ART initiation is associated with increased and more timely 
uptake of ART [33]. This analysis further showed that these 
improvements did not come at the expense of crowding out 
sicker patients. This analysis has recently been updated to include 
settings that have implemented ‘treat all’ and concluded that 
the greatest improvements in timeliness of ART initiation under 
successive guideline expansions that included expansion to ‘treat 
all’ occurred in low-income countries, likely to be due to the 
simplification of initiation decisions, i.e. opening the possibility 
to initiate treatment while waiting for baseline CD4 cell count 
test results. Young people aged 15–25 years also benefited from 
more timely ART initiation under ‘treat all’, as CD4 cell count-
based guidelines disadvantaged this group of patients, who were 
likely to have been recently infected and therefore more likely 
to have higher CD4 cell counts.
experience of implementing ‘treat all’ for pregnant and breast-
feeding women (Option B+) has found that, while the approach 
is feasible across a variety of settings, there is a need to ensure 
For pregnant women with Hiv, a recommendation was made in 
favour of starting ART irrespective of CD4 cell count (PMTCT 
Option B+) [21]. This recommendation, aimed at increasing ART 
uptake among pregnant women, was based on a recognition of 
the need to simplify ART provision during pregnancy and breast-
feeding, and to avoid delays in starting ART in pregnant women 
in settings where CD4 cell count testing was not available or 
where waiting for results could result in missed opportunities to 
prevent vertical transmission. evidence supporting the benefits 
of this approach came from observational studies that provided 
outcomes from programmes implementing Option B+; these studies 
all found that uptake of ART was more timely, and that women 
experienced health benefits in terms of immunological and clinical 
parameters [22–24].
Similarly, ART initiation for all children aged under 5 years was 
recommended to address the low treatment coverage in children; 
however, at the time, this recommendation was made in the 
absence of randomised controlled trial evidence of clinical benefit, 
and primarily on the basis of observed rapid immunological decline 
in the absence of ART as well as causal modelling analysis of 
observational data from Southern Africa [13].
while several observational studies also suggested a clinical benefit 
to providing lifelong ART as soon as possible following an Hiv 
diagnosis [9,25], the wHO recommendation was only made 2 
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adequate retention in care and medication adherence, particularly 
during the first year following ART initiation [34]. This may also 
be a concern for anyone starting ART at higher CD4 cell counts, 
although the evidence so far is mixed [35,36].
implementation of recommendations for rapid ART initiation has 
also been informed by observational data. while the results of 
several randomised trials all favoured rapid ART initiation, in 
particular by reducing the risk of loss to follow-up before ART 
initiation, some observational studies reported increased losses 
to follow-up after ART initiation. This suggests that different 
approaches to adherence counselling after starting ART may be 
needed when ART is started rapidly, as people are still coming 
to terms with their diagnosis. A recent study by the ieDeA col-
laboration in Rwanda suggested that patients enrolling in care 
at sites conducting fewer ART readiness counselling sessions 
initiated ART more rapidly and had better retention 6 months 
post initiation [37].
Identifying gaps in policy and practice
Observational cohorts provide valuable insights into the program-
matic impact of ART scale-up and, in doing so, can reveal gaps 
in the response that are a priority for future intervention research 
and policy guidance.
Several studies from the ieDeA collaboration have highlighted 
the fact that men with Hiv have worse outcomes compared to 
women with Hiv [38,39], and this has contributed to a recogni-
tion of the need to identify models of care to improve uptake 
and outcomes for men [40].
The enduring burden of advanced Hiv disease is another chal-
lenge that has been highlighted through observational research. 
Successive studies by the ieDeA collaboration have shown that, 
despite major progress in ART scale-up, an important proportion 
of patients continues to present late for care, with advanced 
Hiv disease [14,41,42]. This work directly contributed to the 
development of wHO guidance on the management of advanced 
Hiv disease in 2017 [28], and continues to drive discussions 
about how to best promote earlier diagnosis and linkage to care 
globally.
Rapid introduction of new antiretrovirals for which limited experi-
ence has been gathered outside the setting of randomised clinical 
trials requires increasing attention to longer-term monitoring of 
treatment outcomes and toxicity profiles across populations. As 
countries strengthen their pharmaco-vigilance systems to enable 
active monitoring and high-quality surveillance, cohort collabora-
tions such as ieDeA can play a critical role in addressing this 
important evidence gap.
Future research will improve our understanding of the challenges 
faced in implementing the ‘treat all’ policy, in particular whether 
there are differences in adherence, retention, viral suppression 
and viral resistance among people starting ART without having 
developed clinical disease, and the possible need for differential 
adherence support for different patient populations. indeed, 
observational research has the advantage of capturing the experi-
ence and patient outcomes that occur outside the controlled 
environments of research protocols and are critical for policies 
and guidelines, including large populations of persons who are 
not typically recruited into, or represented, in randomised trials, 
but are none the less differentially impacted by the Hiv epidemic, 
such as children, pregnant women, persons with TB, persons with 
mental health and substance use disorders, and marginalised 
populations. Observational cohorts, such as ieDeA, also have the 
advantage of scale and the ability to examine implementation 
and health outcomes in a variety of diverse settings and care 
delivery contexts.
Conclusions
evidence from observational cohorts has made a central contribu-
tion to the development of wHO guidelines, and will continue 
to do so. Observational data can be especially critical for groups 
of people who have not been enrolled in randomised trials in 
addressing a given implementation question, for example, pregnant 
women and children. Randomised trials are also not generally 
well suited for assessing rare harms (owing to limited sample 
sizes and rigorous exclusion criteria), which often only become 
apparent when a drug is being rolled out. in addition, observa-
tional studies provide valuable insights into the feasibility and 
implementation challenges associated with a given intervention 
or set of interventions. Finally, increasing attention is being paid 
to the need to evaluate the uptake and impact of wHO guidelines 
on critical health outcomes in countries (Figure 1). Observational 
studies are well suited to evaluating the impact of policy change 
in routine practice.
The continued contribution of observational data to shaping the 
response to Hiv depends on continued investment in data systems 
by national programmes and international donors. it has been 
recommended that 5–10% of all Hiv programme budgets be 
directed towards data collection and use [43]. Sustained invest-
ment in the generation and analysis of observational data will 
make an important contribution to programme performance, as 
well as helping to inform the global response.
Approaches to data interpretation are being continuously updated 
to improve the reliability of evidence from observational research. 
Collaboration between cohorts across different countries can 
enhance the comparability of findings and their generalisability 
(provided all findings point in the same direction) or point towards 
important sources of heterogeneity (if they do not). Advances 
in statistical software have increased the usage of tools such as 
multiple imputation to analyse incomplete datasets. increased use 
of design and analytical approaches, such as regression disconti-
nuity, difference-in-difference, g-estimation and propensity score 
have helped achieve more analytical rigour for assessing causal 
associations and impact, provided the most critical confounders 
have been directly or indirectly controlled.
The ieDeA–wHO partnership [32] is an example of an effective 
collaboration that can provide valuable insights into whether 
wHO guidelines are making a difference to outcomes for people 
living with Hiv, and guide how future ieDeA analyses can have 
more policy relevance. The potential to expand this collaboration 
to cover other disease areas should be explored.
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